Article Text

other Versions

PDF
Evaluation of a surveillance programme for women with a family history of breast cancer
  1. Marta Moreira Reis (marta.reis{at}nhs.net)
  1. Ninewells Hospital and Medical School, Dundee, United Kingdom
    1. Manouche Tavakoli (mt{at}st-and.ac.uk)
    1. Dept of Management, St Andrews University, United Kingdom
      1. John A Dewar (john.a.dewar{at}nhs.net)
      1. Ninewells Hospital and Medical School, Dundee, United Kingdom
        1. David R Goudie (d.r.goudie{at}dundee.ac.uk)
        1. Ninewells Hospital and Medical School, Dundee, United Kingdom
          1. Alan Cook (alancook{at}nhs.net)
          1. Ninewells Hospital and Medical School, Dundee, United Kingdom
            1. Lorna McLeish (lornamcleish{at}nhs.net)
            1. Ninewells Hospital and Medical School, Dundee, United Kingdom
              1. Dorothy Young
              1. Ninewells Hospital and Medical School, Dundee, United Kingdom
                1. Jane Kenyon
                1. Bute Medical School, University of st Andrews, United Kingdom
                  1. Christopher Michael Steel (cms4{at}st-and.ac.uk)
                  1. Bute Medical School, University of st Andrews, United Kingdom

                    Abstract

                    Purpose: To establish health-related costs and benefits of clinical services for women at increased familial risk of breast cancer.

                    Design: Analysis of costs and outcomes for one UK regional service, supplemented with data from a multi-national collaborative study.

                    Main outcome measures were aggregate costs for regular clinical examination, mammographic screening and further investigations; breast cancer incidence; proportion of cancers detected at “early” or “late” stage, compared with corresponding data for unscreened women of comparable age; survival in relation to stage at diagnosis; itemised and aggregate costs of management for “early” and “late” stage breast cancer; hence direct health care costs per quality adjusted life year (QALY) gained.

                    Results: The surveillance programme costs £1500 per woman (over 15 years). Breast cancer incidence is close to 6 per thousand examinations; 75% of tumours are detected through screening and 77% are “early” (path stage 1 or 2). Corresponding figures for unscreened women (including relatives of those attending the breast cancer family clinic) indicate that surveillance achieves a beneficial “stage shift”, with reduction in treatment costs and improvement in survival, in about 22% of cases.

                    Conclusions: The current clinical service for women at familial risk of breast cancer costs about £4800 per QALY gained. That figure is sensitive to the rate of detection of breast cancer and the degree of beneficial stage shift achieved. Within the realistic range of estimates for these two parameters, the cost per QALY may be as high as £14000 or as low as £1000.

                    Statistics from Altmetric.com

                    Request permissions

                    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.